Pfizer Inc.(PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest News & Analysis
Pfizer Escalates Cost Discipline: $7.7B Savings Programme Validates Metsera Investment
$7.7B cost programme escalation validates Metsera investment and dividend sustainability through obesity market entry.
Pfizer Completes Metsera Entry and Harvests COVID Wealth Amid Portfolio Rebalancing
Metsera deal closes with shareholder approval; BioNTech 54.7% stake reduction confirms capital rotation from COVID to obesity.
Pfizer's Metsera Victory: Litigation Vindication at the Cost of Capital Discipline
FTC-backed litigation victory halts Novo bid, yet $4.4B cost escalation challenges capital discipline commitment.
Pfizer's Federal Antitrust Gambit: Dual-Track Litigation Escalates Metsera Defence
Pfizer files second lawsuit within 72 hours, escalating deal defence to federal antitrust claims and testing management conviction under competitive pressure.
Pfizer's Litigation Gambit: Metsera Deal Defence Tests Capital Discipline Conviction
Pfizer files Delaware lawsuit to block Novo Nordisk's counterbid hours after FTC approval, signalling management resolve but intensifying execution risk.
Pfizer's Obesity Bet Under Siege: Metsera Deal Faces Novo Nordisk Rival Bid
Novo Nordisk's $9B counteroffer for Metsera threatens Pfizer's obesity strategy and tests management conviction under M&A pressure.
Pfizer's Portfolio Pivot Gains Momentum: Oncology Validation and Q3 Strength Converge
Clinical wins and non-oncology forecasts signal Pfizer's successful transition away from COVID dependency, validating the Seagen integration thesis.
Pfizer Faces Scrutiny Amidst Drug Developments & Headwinds
A comprehensive intraday analysis of Pfizer covering legal scrutiny, breakthrough clinical trials, dividend yields, and strategic market responses.
Pfizer: Navigating Oncology, Dividends, and Regulatory Challenges in 2025
A detailed data-driven update on Pfizer’s latest developments, clinical breakthroughs, and regulatory challenges affecting [PFE](/dashboard/companies/PFE).
Pfizer's Strategic Pivot: Gene Therapy Setback and Oncology Focus
Pfizer navigates strategic shifts, ending gene therapy development while focusing on oncology amid legal scrutiny, impacting investor sentiment and future prospects.
Pfizer's Strategic Shift: Pipeline Adjustments and Market Impact
A comprehensive, data-driven update on Pfizer Inc.'s strategic pivot, pipeline realignment, legal investigations, and market challenges.
Pfizer's Strategic Shift: Oncology, Regulatory Expertise, and Dividend Prospects
Pfizer focuses on oncology with Ivonescimab, appoints Patrizia Cavazzoni as CMO, and navigates vaccine demand and legal challenges, maintaining investor appeal.
Pfizer: Oncology Strategy, Regulatory Changes, and Market Outlook
Pfizer focuses on oncology via collaborations, addresses coronavirus concerns, and faces a Depo-Provera probe. Cavazzoni's CMO role could streamline approvals, while value stocks gain traction.
Pfizer's Strategic Shift: Oncology Focus & Vaccine Pipeline
Pfizer strategically focuses on oncology via collaborations like Summit Therapeutics, navigating regulatory changes and new coronavirus variants. Legal challenges and vaccine demand present risks.
Pfizer Inc.: Intraday Updates and Key Developments
Pfizer intraday update reveals robust revenue growth, dividend strength and legal challenges shaping its strategic trajectory.
Pfizer (PFE): Oncology Breakthroughs, Financial Resilience, Dividend
Pfizer Inc. (PFE) navigates oncology breakthroughs, financial resilience, and dividend sustainability amidst challenges. Strategic collaborations and cost-cutting are crucial.
Pfizer (PFE): Sales, China, and Apretude Strategy Analysis
Pfizer (PFE) navigates post-pandemic market via sales revamp, China focus, Apretude. Financial analysis reveals fluctuating profitability. Valuation gap suggests undervaluation. Investors monitor catalysts.
Pfizer's Strategic Reset: Haleon Divestiture, China Expansion, and Dividend Outlook
Pfizer navigates strategic shifts: Haleon divestiture, China expansion, and dividend sustainability in a dynamic pharmaceutical landscape.
Pfizer (PFE): Strategic Shifts, Dividend Outlook, and Growth
Pfizer (PFE) navigates strategic shifts, a compelling dividend, and growth challenges. This analysis explores valuation, market sensitivity, and strategies to mitigate trade war risks.
Pfizer (PFE): Strategic Shift, Pipeline Focus, and Growth Outlook
Pfizer's strategic shift, pipeline focus, and dividend appeal analyzed. Learn how these factors shape its growth outlook and investment potential.
Pfizer (PFE): ABRYSVO Approval, Tariff Risks, and Dividend Dilemma
Pfizer Inc. (PFE) navigates EU approval of ABRYSVO, tariff threats, and dividend sustainability concerns amid ETF shifts. A deep dive into PFE's strategic response.
Pfizer (PFE): Navigating Legal Hurdles, Stock Volatility, and Future Growth
Pfizer (PFE) faces challenges but the GSK lawsuit resolution and cost-cutting offer upsides. High dividend yield may attract investors, but volatility and tariffs warrant caution.
Pfizer ([PFE](/dashboard/companies/PFE)) Financial Analysis: Cost Control, Pipeline & Dividend Outlook
Deep dive into Pfizer's latest financials and strategy, analyzing recent earnings, cost controls, oncology pipeline, patent challenges, and dividend sustainability.
Pfizer ([PFE](/dashboard/companies/PFE)) Navigates Legal Scrutiny & Oncology Growth
Pfizer ([PFE](/dashboard/companies/PFE)) faces fiduciary duty probes while advancing its oncology pipeline. Learn how legal challenges and strategic growth impact its market position.
Pfizer's Strategic Oncology Push Amidst Mounting Legal Headwinds
Pfizer navigates oncology growth, fueled by Seagen, against legal challenges, vaccine policy shifts, and a high dividend yield raising sustainability questions.
Pfizer (PFE): Innovation, Litigation, and Market Dynamics in 2025
Pfizer navigates a complex landscape in 2025, balancing new drug successes and the Seagen acquisition with significant legal challenges.
Pfizer (PFE): Navigating Patent Expirations and Regulatory Shifts
Pfizer faces a critical juncture in 2025, navigating significant patent expirations and a volatile regulatory landscape following recent vaccine panel changes.
Pfizer's Hympavzi: A Data-Driven Catalyst for Hemophilia Treatment
Pfizer's Hympavzi, with its 93% bleeding reduction in trials, signals a strategic pivot and potential financial turnaround for the pharma giant.
Pfizer Inc. Strategic Shift with $6.7B Arena Pharma Acquisition and Cannabis Market Expansion
Pfizer's $6.7B acquisition of Arena Pharmaceuticals marks a key pivot into medical cannabis, backed by robust financials and a promising cannabinoid pipeline.
Pfizer Inc. Market Update: Vaccine Delay Probe, Financial Strength, and Strategic Outlook
Pfizer faces a House probe over COVID-19 vaccine timing amid strong financials and strategic moves. Analyze market impact, financials, and future outlook.
Pfizer Inc. (PFE) Dividend Sustainability and Pipeline Growth: A Data-Driven Market Analysis
Analyze Pfizer's dividend sustainability, financial health, pipeline strategy, and market positioning amid patent cliffs and legal challenges in this comprehensive update.
Pfizer Inc. Patent Appeal and Financial Overview: Strategic Implications for Investors - Monexa AI
Detailed analysis of Pfizer's patent appeal against Moderna, financial performance, and strategic outlook shaping its competitive position in the mRNA vaccine market.
Pfizer Inc. Dividend Sustainability and Financial Health Analysis - Monexa AI
Pfizer's high dividend yield at 6.7% is supported by cash flow but challenged by payout ratio over 120%, legal risks, and competitive pressures.
Pfizer Inc. (PFE) Latest Financial and Strategic Update: Earnings, Debt, and Market Position
Pfizer Inc. reports strong earnings growth and strategic shifts in 2024, with rising revenues, increased R&D investment, and evolving debt structure shaping its market stance.
Pfizer Inc. Financial Update: Oncology Pipeline, Patent Challenges, and Dividend Sustainability
Pfizer advances its oncology pipeline with promising candidates and biomarker validation while navigating patent cliffs and maintaining a strong dividend yield.
Pfizer Inc. Growth Strategy and Financial Analysis: Oncology, AI, and Market Position
Explore Pfizer's strategic oncology expansion, AI innovation, and financial health amid challenges like litigation and COVID-19 revenue declines.
Pfizer Inc. Eliquis Pricing Strategy and Financial Impact Analysis | Monexa AI
Explore Pfizer's Eliquis direct-to-patient pricing strategy, its financial impact, competitive positioning, and dividend sustainability backed by latest data.
Pfizer Inc. Market Update: Navigating U.S. Drug Pricing Pressure and Sustaining Dividends Amid Innovation Challenges
Pfizer faces intense U.S. drug pricing pressure, balancing innovation, dividend sustainability, and cost management to maintain market position and investor confidence.
Pfizer Inc. Q2 2025 Earnings Surge and Dividend Sustainability Analysis - Monexa AI
Pfizer's Q2 2025 earnings beat signals growth with strong vaccine and oncology sales. Dividend sustainability faces scrutiny amid patent cliffs and policy headwinds.
Pfizer Inc. Q2 2025 Earnings Beat and Strategic Update: Navigating Growth and Dividend Sustainability
Pfizer's Q2 2025 earnings beat expectations with strong revenue growth and raised guidance, highlighting operational efficiency and pipeline strength amid dividend sustainability concerns.
Pfizer Inc. — Earnings, Dividend Sustainability & Strategic Moves
Data-driven update on Pfizer's earnings beats, cash-flow profile, dividend sustainability, balance-sheet shifts and strategic implications for investors.
Pfizer Inc. — Padcev Trial Win and 2025 Financial Update
Padcev’s late‑stage win, raised 2025 guidance and a +6.84% revenue recovery reshape Pfizer’s cash‑flow profile; dividend yield +6.95% and net debt/EBITDA 2.64x are key watchpoints.
Pfizer Inc. Patent Cliff Strategy and Oncology Growth Analysis | Monexa AI
Pfizer navigates a $15-18B patent cliff with oncology expansion, Seagen acquisition, and $7.7B cost savings, balancing R&D reinvestment and legal risks.
Pfizer Inc. Patent Cliff Strategy and Oncology Expansion: A Data-Driven Financial Update
Pfizer navigates significant patent expirations with a $7.7B cost-saving plan and $43B Seagen acquisition to strengthen its oncology pipeline and sustain dividends.
Pfizer Inc. (PFE): Post‑Pandemic Normalization, Cash Flow Strength and a Heavy Dividend Load
Pfizer’s 2024 results show revenue stabilization at **$63.63B**, stronger free cash flow and a stretched dividend payout amid portfolio reshaping and mixed balance‑sheet signals.
Pfizer Inc. (PFE) — Earnings, Cash Flow and the Oncology Gamble
Pfizer posted **$63.63B** revenue in 2024 and **$9.84B** free cash flow — coverage for a **6.78%** yield is tight as a concentrated 2026 patent cliff and litigation risk collide with the Seagen-driven oncology pivot.
Pfizer Inc.: Post‑Pandemic Pivot, Seagen Debt and the Oncology Growth Math
Pfizer reported **$63.63B** revenue and **$8.02B** net income for FY2024 while taking on **~$31B** of debt for Seagen—turning the pandemic hangover into an oncology growth bet.
Pfizer Inc. (PFE): Earnings Recovery, Dividend Durability and the Oncology Pivot
Pfizer reported Q2 2025 revenue of $14.7B and adjusted EPS $0.78, raised FY EPS guidance — the company is pivoting cash toward oncology while defending a near‑7% yield.
Pfizer Inc. (PFE): FY2024 Turnaround, Cash Flow and Dividend Health
Pfizer posted **$63.63B** revenue in FY2024 (+6.86% YoY) and **$8.02B** net income (+276% YoY); free cash flow of **$9.84B** underpins a **6.96%** yield but leverage rose.